Evolus (NASDAQ:EOLS) Receives Buy Rating from HC Wainwright

by · The Cerbat Gem

HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a report issued on Friday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Several other equities research analysts also recently weighed in on EOLS. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Finally, Mizuho cut their target price on Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Monday, December 1st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Evolus presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

Read Our Latest Report on EOLS

Evolus Price Performance

Shares of EOLS stock opened at $5.65 on Friday. The company has a market cap of $366.23 million, a PE ratio of -6.14 and a beta of 0.91. Evolus has a 1 year low of $5.13 and a 1 year high of $17.12. The stock’s 50 day simple moving average is $6.80 and its two-hundred day simple moving average is $7.31.

Evolus (NASDAQ:EOLS – Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. The company had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. Equities research analysts expect that Evolus will post -0.61 EPS for the current year.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the transaction, the insider directly owned 354,388 shares in the company, valued at $2,533,874.20. This trade represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Evolus

Institutional investors have recently made changes to their positions in the company. Manchester Capital Management LLC bought a new stake in shares of Evolus in the second quarter valued at about $26,000. State of Alaska Department of Revenue bought a new stake in shares of Evolus in the 3rd quarter valued at about $26,000. Wexford Capital LP purchased a new stake in shares of Evolus in the 3rd quarter worth approximately $37,000. Tower Research Capital LLC TRC boosted its stake in shares of Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after purchasing an additional 5,691 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Evolus during the third quarter valued at approximately $48,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

(Get Free Report)

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

Recommended Stories